Main Article Content


Nanoparticles represent a promising drug delivery system of sustained and targeted drug release. They are specially designed to release the drug in the vicinity of target tissue. The aim of this study was to prepare and evaluate PLGA nanoparticles containing Lamivudine in different drug to polymer ratio. SEM indicated that nanoparticles have a discrete spherical structure. FT-IR studies indicated that there was no chemical interaction between drug and polymer and stability of drug. The in vitro release behavior from all the drug loaded batches was found to be Higuchi release and provided sustained release over a period of 12 h. The developed formulation overcome and alleviates the drawbacks and limitations of Lamivudine sustained release formulations and could possibility be advantageous in terms of increased bioavailability of Lamivudine.


Nanoparticles Lamivudine biodegradable

Article Details

How to Cite
Gummadi Hema Sri, D. Appalaraju, & B. Sravanasree. (2023). Formulation and in vitro evaluation of lamivudine loaded nanoparticles. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(3), 157-165.


  1. 1. Remington: the science and practice of pharmacy. 20th ed Alfonso R, editor Gennaro Published by Lippincot Williams and Wilkins. Vol. 1. Philadelphia: Page No. 903; 2000.
  2. 2. Controlled drug delivery fundamentals and applications. 2nd ed Robonson JR, Lee VHL, editors. New York: Dekker, 1987; Page No. 3.
  3. 3. Controlled and novel drug delivery. 1st ed Jain NK, editor. CBS Publishers & New Delhi: Distributors, 1997; Page No. 1.
  4. 4. The theory & practice of industrial pharmacy. 3rd ed Lachman L, Liberman HA, Joseph L, editorsKanig Published by. Bombay: Varghese Publishing House, 1991; Page No. 430-439.
  5. 5. Targeted and controlled drug delivery novel carrier systems. 1st ed Vyas SP, Khar RK, CBS, editors Publishers & Distributors. Vol. 39. New Delhi: Page; 2002.
  6. 6. Basak SC. Novel drug delivery systems. Indian Pharm. April 2005:7-10.
  7. 7. Pharmaceutical biotechnology. 1st ed Vyas SP, Dixit VK, editors, Published by CBS Publishers & Distributors. Vol. 395. New Delhi: Page; 1998.
  8. 8. Encyclopedia of pharmaceutical technology. 2nd ed Fattal E, Vauhier C, editors. Published by. New York: Marcel Dekker, Inc, 2002; pg (1864).
  9. 9. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog Polym Sci. 2007;32(8-9):762-98. doi: 10.1016/j.progpolymsci.2007.05.017.
  10. 10. Mohanraj VJ, Chen Y. Nanoparticles – a review. Trop J Pharm Res. June 2006;5(1):561-73. doi: 10.4314/tjpr.v5i1.14634.
  11. 11. Singh R, Lillard JW Jr.. Nanoparticle-based targeted drug delivery Exp Mol Pathol. 2009;86(3):215-23. doi: 10.1016/j.yexmp.2008.12.004, PMID 19186176.
  12. 12. Peltonen L, Aitta J, Hyvönen S, Karjalainen M, Hirvonen J. Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of Poly(l)lactide nanoparticles. AAPS PharmSciTech. 2004;5(1):article 16. doi: 10.1208/pt050116, PMID 15198537.
  13. 13. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. November 15 2006;325(1-2):172-9. doi: 10.1016/j.ijpharm.2006.06.023, PMID 16887303.
  14. 14. Liancy L, Si-Shen F, Hsing SP. Nanoparticles of Biodegradable polymers Applied for clinical Administration of Anti cancer Drugs. Available from: [UROP report].
  15. 15. Mu L, SS. Feng worked on A novel controlled release formulation for the anticancer drug paclitaxel(taxol);PLGA nanoparticles containing Vit E TPGS. J Control Release. 2003;86:33-48.
  16. 16. Jawahar N, Eagappanath T, Nagasamy Venkatesh J. S, Samanta M. K, worked on preparation and characterization of PLGA-Nanoparticles containing Anti-hypertensive agents. Int J PharmTech Res. 2009;1(2, April-June):390-3.
  17. 17. Pillai RR, Somayaji SN, Rabinovich M, Hudson MC, Gonsalves KE. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed Mater. 2008;3(3):034114 (7pp). doi: 10.1088/1748-6041/3/3/034114, PMID 18708713.
  18. 18. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. May 24 2007;336(2):367-75. doi: 10.1016/j.ijpharm.2006.11.061, PMID 17207944.
  19. 19. Esmaeili F, Atyabi F, and Dinarvand R.l worked on Preparation and characterization of estradiol loaded PLGA nano particles using homogenization solvent diffusion method. DARU Vol. 16, No. 4 2008 page no 196-202.
  20. 20. Swati SS sashmal, Swarupananda Mukherjee, Subhabrata Ray, Ram Sharnagat Thakur, Lakshmi K.Ghosh and Bijan K.Gupta worked on design and optimization of NSAIDS loaded nanoparticles. Pak. J. Pharm. Sci., 2007, Vol.20(2), 157-162.
  21. 21. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. July 13 2007;120(1-2):18-26. doi: 10.1016/j.jconrel.2007.03.012, PMID 17509712.
  22. 22. Bhokare SG, Marathe RP. Rosuvastatin calcium loaded chitosan nanoparticles: preparation evaluation and in vitro release studies. Int J App Pharm. 2020;12(5):95-102. doi: 10.22159/ijap.2020v12i5.38175.
  23. 23. Suganya T. Formulation and evaluation of polymeric nanoparticles as carriers of rosuvastatin calcium for oral administration; May 2012.
  24. 24. Merck. Index. 13th ed. Vol. 3431.
  25. 25. Rowe RC, sheskey PJ. Hand book of pharmaceutical excipients pg. 1569;2041:80.